Clinical Trial ID: NCT05609370
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Status
Open
Conditions
Other
Phases
II
Age Group
Adult
Main Investiagtor
Zaiden, Robert
Practice
GI
Scope
National
Nct ID Number
NCT05609370
Secondary Trial ID Number
BGB-A317-LBL-007-201
Keywords
Treatment